EASL 2014: Hepatitis C players seek the spotlight | PharmaBoardroom
written on 25.03.2014
Tags:
,

EASL 2014: Hepatitis C players seek the spotlight

TAGS: ,

Sovaldi (sofosbuvir) likely will maintain its market-leading presence, but abstracts for EASL presentations show that AbbVie's late-stage therapies and Merck's mid-stage compounds also are capable of performing well in patients with the hepatitis C virus…

Latest Report